Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study

BMC Psychiatry

Table 2 Current dispositions and medications of the study participants

	Non-TRS (Group 1)		TRS without CR (Group 2)		TRS with CR (Group 3)		Group comparisons^†	Significant post hoc comparisons^‡
Variables	(N = 102)		(N = 48)		(N = 54)		p
	Mean	(SD)	Mean	(SD)	Mean	(SD)
Current antipsychotic medication dosage, CPZE, (mg/day)	358.5	(185.8)	458.3	(329.5)	370.8	(186.8)	0.0397	1 < 2
Clozapine current dosage (mg/day)			283.6	(91.9)	322.5	(89.0)	0.0682
Clozapine current dosage (mg/day)	N	(%)	N	(%)	N	(%)
Current disposition							< 0.0001	1 ≠ 2 ≠ 3
Chronic ward	9	(8.8)	36	(75.0)	53	(98.1)
Out-patient department	86	(84.3)	12	(25.0)	1	(1.9)
Acute ward	7	(6.9)	0	(0)	0	(0)
Polypharmacy	3	(2.9)	15	(31.3)	12	(22.2)	< 0.0001	1 < 2, 1 < 3
Atypical-antipsychotic user	54	(52.9)	38	(79.2)	50	(92.6)	< 0.0001	1 < 2, 1 < 3
Clozapine use							< 0.0001	1 ≠ 2 ≠ 3
Never-user	102	(100)	17	(35.4)	0	(0)
Ever-user	0	(0)	2	(4.2)	4	(7.4)
Current-user	0	(0)	29	(60.4)	50	(92.6)

TRS treatment-resistant schizophrenia, CR clozapine resistance, CPZE chlorpromazine equivalent
^†ANOVA for continuous variables in 3-group comparisons; t-test for continuous variables in 2-group comparisons; χ² test or Fisher’s exact test for categorical variables
^‡Tukey’s HSD test in ANOVA; a Tukey-type multiple comparison for proportions in a 2*3 cross-tabulation for categorical variables [43]; multiple comparisons with Fisher’s combination test in a 3*3 cross-tabulation for categorical variables

ISSN: 1471-244X